Scanlon Meghan
Known title: SVP,Pres,Urology Pelvic HealthCIK: 0001801586
Associated companies
Transaction History
| BSX | ▲ Buy | Option Exercise | 2,062 | $0 | 5/1/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 606 | $26K | 5/1/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,019 | $0 | 2/28/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 300 | $13K | 2/28/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 779 | $0 | 2/21/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 229 | $10K | 2/21/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 327 | $14K | 2/18/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,112 | $0 | 2/18/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,583 | $0 | 2/17/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 494 | $21K | 2/17/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,108 | $0 | 2/15/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 388 | $17K | 2/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.